Publication Name	World Journal of Gastroenterology
Manuscript ID	20229
Country	Italy

Received	2015-05-30 12:20
Peer-Review Started	2015-06-04 08:14
To Make the First Decision	2015-07-14 11:50
Return for Revision	2015-07-27 19:06
Revised	2015-09-03 17:25
Second Decision	2015-11-03 09:05
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-11-19 16:36
Articles in Press	2015-11-19 16:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-28 12:27
Publish the Manuscript Online	2016-01-15 14:54

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Review
Article Title	Pharmacokinetic drug interactions in liver disease: An update
Manuscript Source	Invited Manuscript
All Author List	Pietro Palatini and Sara De Martin
Funding Agency and Grant Number
Corresponding Author	Pietro Palatini, PhD, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo E. Meneghetti 2, 35131 Padova, Italy. pietro.palatini@unipd.it
Key Words	Pharmacokinetic interactions; Enzyme inhibition; Enzyme induction; Liver disease; Plasma protein binding
Core Tip	The widespread use of polypharmacotherapy makes drug-drug interactions due to inhibition or induction of drug-metabolizing enzymes virtually unavoidable, with consequently high risk of serious or even life-threatening adverse effects. An appropriate management of such interactions by dose adjustment is made difficult by their high interindividual variability. This review, which focuses on the variability associated with liver functional status, presents an updated discussion of the relevant literature, analyzes the mechanisms responsible for the effect of liver dys-function on the magnitude of these interactions, and outlines the criteria on which their clinical management should be based.
Publish Date	2016-01-15 14:54
Citation	Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: An update. World J Gastroenterol 2016; 22(3): 1260-1278
URL	http://www.wjgnet.com/1007-9327/full/v22/i3/1260.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i3.1260

Full Article (PDF)	WJG-22-1260.pdf
Full Article (Word)	WJG-22-1260.doc
Manuscript File	20229-Review.docx
Answering Reviewers	20229-Answering reviewers.pdf
Audio Core Tip	20229-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	20229-Conflict-of-interest statement.pdf
Copyright License Agreement	20229-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	20229-Language certificate.pdf
Peer-review Report	20229-Peer-review(s).pdf
Scientific Misconduct Check	20229-Scientific misconduct check.pdf
Scientific Editor Work List	20229-Scientific editor work list.pdf